Medroxyprogesterone acetate capsule and preparation method thereof
Medicated progesterone acetate capsules are prepared by combining medroxyprogesterone acetate with hydrophilic materials, fillers, disintegrants and lubricants, which solves the problems of low dissolution rate and bioavailability of existing preparations, and achieves more Fast drug absorption rate and higher dissolution.
Patent Information
- Application Number
- CN202310567086.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-19
- Publication Date
- 2024-11-22
AI Technical Summary
The current medroxyprogesterone acetate preparations have low dissolution rate and bioavailability, resulting in slow drug absorption rate.
Using a combination of medroxyprogesterone acetate, hydrophilic materials, fillers, disintegrants, lubricants and glidants, solid dispersion particles are made by spray drying, and are disintegrated with fillers and disintegrants in a high-efficiency mixer. After mixing the agent and lubricant, the capsule is filled, and the mixed solution of ethanol and trichloromethane is used to improve the solubility and dispersion of the drug.
It significantly improves the dissolution and bioavailability of medroxyprogesterone acetate, shortens the disintegration time of the drug, improves the absorption rate in the body, and meets higher dissolution requirements.
Smart Images

Figure BDA0004237110900000031 
Figure BDA0004237110900000041 
Figure BDA0004237110900000042
Abstract
Description
Technical Field
[0001] The invention relates to the field of biotechnology, and in particular to a medroxyprogesterone acetate capsule and a preparation method thereof. Background Art
[0002] Medroxyprogesterone acetate, also known as progesterone acetate, is an organic compound with a chemical formula of C 24 H 34 O4 is mainly used for dysmenorrhea, functional amenorrhea, functional uterine bleeding, threatened abortion or habitual abortion, endometriosis, treatment of advanced breast cancer, endometrial adenocarcinoma and renal cancer, etc. It can be used as a long-acting contraceptive injection when used in large doses. After the endometrium loses the support of estrogen and progesterone and falls off during menstruation, medroxyprogesterone acetate can continue to artificially supplement estrogen or progesterone, especially progesterone, so that the "helpless" endometrium continues to be supported and maintains a level of continuous thickening. In this way, the endometrium grows firmly on the uterine wall, preparing for the implantation of the fertilized egg, and achieving the purpose of delaying menstruation.
[0003] Breast cancer and endometrial adenocarcinoma are the most common gynecological malignancies. Medroxyprogesterone acetate can be used as an endocrine therapy drug for hormone-dependent tumors such as breast cancer and endometrial cancer. It is currently widely used in clinical practice and has achieved satisfactory results. Medroxyprogesterone acetate is a white or off-white crystalline powder, which is easily soluble in chloroform, soluble in acetone, slightly soluble in ethyl acetate, slightly soluble in anhydrous ethanol, and insoluble in water.
[0004] At present, patent CN1887288A discloses a drug for treating endometriosis and a preparation method thereof, wherein the drug is made into dispersible tablets, which are composed of medroxyprogesterone acetate, sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone, pregelatinized starch, microcrystalline cellulose, silicon dioxide and an appropriate amount of 5% polyvinylpyrrolidone ethanol solution; in the preparation method of the patent, medroxyprogesterone acetate is directly mixed with fillers, disintegrants, lubricants and other drug excipients to form a soft material, granulate, dry, and tablet to form ordinary dispersible tablets or ordinary capsules, and the drug dissolution rate is low and the in vivo absorption rate is slow. Patent CN101480401A discloses medroxyprogesterone acetate tablets and a preparation method thereof. The tablets contain medroxyprogesterone acetate and an appropriate amount of pharmaceutical excipients, wherein the pharmaceutical excipients are selected from fillers, binders, disintegrants and lubricants, and the lubricants may be magnesium stearate and polyethylene glycol-4000. Although the patent uses hydrophilic excipients lactose and sodium carboxymethyl starch to improve the disintegration and dissolution of the tablets, the dissolution rate of the tablets prepared by the conventional preparation process is slow and the bioavailability is low due to the poor solubility of the raw material itself. Summary of the invention
[0005] The object of the present invention is to provide a medroxyprogesterone acetate capsule and a preparation method thereof, which improves the disintegration rate and dissolution rate of medroxyprogesterone acetate while ensuring the absorption rate of the drug in the body, thereby solving the problems in the prior art.
[0006] To achieve this object, the present invention adopts the following technical solutions:
[0007] The first aspect of the present invention provides a medroxyprogesterone acetate capsule, comprising medroxyprogesterone acetate, a hydrophilic material, a filler, a disintegrant, a lubricant, a glidant and a solvent, wherein the hydrophilic material is selected from one of povidone K30, povidone K90, polyethylene glycol-4000 or polyethylene glycol-6000.
[0008] As an embodiment of the present invention, the filler includes one or more of pregelatinized starch and microcrystalline cellulose; the disintegrant includes one or more of sodium carboxymethyl starch, cross-linked sodium carboxymethyl cellulose, and low-substituted hydroxypropyl cellulose; the lubricant includes magnesium stearate; and the glidant includes silicon dioxide.
[0009] As an embodiment of the present invention, the hydrophilic material is povidone K30. The hydrophilic material has polar groups and strong affinity, which is beneficial to improving the dissolution and bioavailability of medroxyprogesterone acetate.
[0010] As an embodiment of the present invention, the solvent includes a mixed solution of ethanol and chloroform, wherein the volume ratio of ethanol to chloroform is 5: 1. The solvent, as an organic reagent, helps to dissolve medroxyprogesterone acetate and povidone K30, thereby better helping to evenly disperse medroxyprogesterone acetate and povidone K30.
[0011] As an embodiment of the present invention, the weight content of each component of the medroxyprogesterone acetate capsule is: 100 parts of medroxyprogesterone acetate, 60-140 parts of hydrophilic material, 1-80 parts of filler, 6-18 parts of disintegrant, 1.5-10.5 parts of lubricant, 3-15 parts of glidant, and 600-1000 parts of solvent.
[0012] As an embodiment of the present invention, the weight content of each component of the medroxyprogesterone acetate capsule is: 100 parts of medroxyprogesterone acetate, 60-140 parts of povidone K30, 6-18 parts of sodium carboxymethyl starch, 1.5-10.5 parts of magnesium stearate, 3-15 parts of silicon dioxide, and 600-1000 parts of a mixed solution of ethanol and chloroform; in the filler, 1-80 parts of microcrystalline cellulose and / or 1-80 parts of pregelatinized starch.
[0013] The second aspect of the present invention provides a method for preparing medroxyprogesterone acetate capsules, the preparation method comprising the following steps:
[0014] Step 1: Mixing medroxyprogesterone acetate, a hydrophilic material and a solvent to completely dissolve them to form a homogeneous solution;
[0015] Step 2: spray drying the homogenized solution to obtain solid dispersion particles;
[0016] Step 3: sieving the solid dispersion particles and mixing them with a filler, a disintegrant, a lubricant and a glidant to form a mixture;
[0017] Step 4: Add the mixture into a high-efficiency mixer, disperse it evenly, and then fill it into capsules.
[0018] As an embodiment of the present invention, in step 1, the mixing time is 5-10 minutes, preferably 10 minutes. The specific mixing time is adaptively adjusted according to the feeding scale.
[0019] As an embodiment of the present invention, in the step 2, the termination condition of the drying is that the residual ethanol content is less than 0.4% and the residual chloroform content is less than 0.1%.
[0020] As an embodiment of the present invention, in the step three, the solid dispersion particles are passed through a 20-100 mesh sieve, preferably a 60 mesh sieve.
[0021] As an embodiment of the present invention, in step 3, the solid dispersion particles are first mixed with a filler and a disintegrant, wherein the mixing time can be selected to be 10-20 minutes; then a lubricant and a glidant are added for mixing, wherein the mixing time can be selected to be 3-5 minutes. The specific mixing time is adaptively adjusted according to the feeding scale.
[0022] Compared with the prior art solutions, the present invention has the following beneficial effects:
[0023] 1. The present invention uses a hydrophilic material as a carrier to first prepare medroxyprogesterone acetate solid dispersion particles, and then mixes the solid dispersion particles with a filler, a disintegrant, a lubricant, a lubricant, and a glidant evenly and performs capsule filling; first preparing the solid dispersion particles and then performing capsule filling is beneficial to significantly improve the solubility of medroxyprogesterone acetate and improve the absorption rate of the drug in the body.
[0024] 2. The hydrophilic material of the present invention is selected from povidone 30, povidone 90, polyethylene glycol-4000, and polyethylene glycol-6000. The hydrophilic material has a polar group and has a strong affinity, thereby improving the solubility and bioavailability of medroxyprogesterone acetate.
[0025] 3. The present invention uses a mixed solution of ethanol and chloroform to dissolve medroxyprogesterone acetate and povidone. The advantage is that the mixed solution of ethanol and chloroform as an organic reagent helps to dissolve medroxyprogesterone acetate and povidone, and the organic reagent itself has a low boiling point and is easy to remove, thereby better exerting the role of the hydrophilic material. DETAILED DESCRIPTION
[0026] The present invention is further described below in conjunction with examples, but the embodiments of the present invention are not limited thereto.
[0027] The equipment or other reagents / materials used in the examples can be purchased through commercial channels.
[0028] The dissolution rate of the present invention is measured by the dissolution and release rate determination method under the dissolution test item of medroxyprogesterone acetate capsules (the second method of Chinese Pharmacopoeia General Rules 0931).
[0029] Dissolution conditions: Use 900 ml of 0.5% sodium dodecyl sulfate as the dissolution medium, rotate at 50 revolutions per minute, operate according to the law, and take samples at 5 minutes, 10 minutes, 20 minutes, 30 minutes, 45 minutes, and 1 hour respectively.
[0030] Example 1
[0031] The present embodiment provides a medroxyprogesterone acetate capsule and a preparation method thereof, the preparation method comprising the following steps:
[0032] Step 1: 100 parts of medroxyprogesterone acetate and 100 parts of povidone K30 are mixed with 600 parts of a mixed solution of ethanol and chloroform (500 parts of ethanol and 100 parts of chloroform) to completely dissolve them for 10 minutes to form a homogeneous solution;
[0033] Step 2: spray drying the homogenized solution until the residual ethanol content is less than 0.4% and the residual chloroform content is less than 0.1%, to obtain solid dispersion particles;
[0034] Step 3: Pass the solid dispersion particles through a 60-mesh sieve, mix with 40 parts of pregelatinized starch, 40 parts of microcrystalline cellulose, and 12 parts of sodium carboxymethyl starch for 15 minutes, and then add 6 parts of magnesium stearate and 9 parts of silicon dioxide and mix for 4 minutes to form a mixture;
[0035] Step 4: Add the mixture into a high-efficiency mixer, disperse it evenly, and then fill it into capsules.
[0036] The relevant indicators of the obtained capsules are shown in Table 1.
[0037] Table 1 Dissolution index obtained in Example 1
[0038]
[0039]
[0040] Example 2
[0041] The present embodiment provides a medroxyprogesterone acetate capsule and a preparation method thereof, the preparation method comprising the following steps:
[0042] Step 1: 100 parts of medroxyprogesterone acetate, 100 parts of polyethylene glycol-4000 and 600 parts of a mixed solution of ethanol and chloroform (500 parts of ethanol and 100 parts of chloroform) are mixed to completely dissolve them for 10 minutes to form a homogeneous solution;
[0043] Step 2: spray drying the homogenized solution until the residual ethanol content is less than 0.4% and the residual chloroform content is less than 0.1%, to obtain solid dispersion particles;
[0044] Step 3: Pass the solid dispersion particles through a 60-mesh sieve, mix with 40 parts of pregelatinized starch, 40 parts of microcrystalline cellulose, and 12 parts of sodium carboxymethyl starch for 15 minutes, and then add 6 parts of magnesium stearate and 9 parts of silicon dioxide and mix for 4 minutes to form a mixture;
[0045] Step 4: Add the mixture into a high-efficiency mixer, disperse it evenly, and then fill it into capsules.
[0046] The relevant indicators of the obtained capsules are shown in Table 2.
[0047] Table 2 Dissolution index obtained in Example 2
[0048]
[0049] Example 3
[0050] The present embodiment provides a medroxyprogesterone acetate capsule and a preparation method thereof, the preparation method comprising the following steps:
[0051] Step 1: 100 parts of medroxyprogesterone acetate and 100 parts of povidone K90 are mixed with 600 parts of a mixed solution of ethanol and chloroform (500 parts of ethanol and 100 parts of chloroform) to completely dissolve them for 10 minutes to form a homogeneous solution;
[0052] Step 2: spray drying the homogenized solution until the residual ethanol content is less than 0.4% and the residual chloroform content is less than 0.1%, to obtain solid dispersion particles;
[0053] Step 3: Pass the solid dispersion particles through a 60-mesh sieve, mix with 40 parts of pregelatinized starch, 40 parts of microcrystalline cellulose, and 12 parts of sodium carboxymethyl starch for 15 minutes, and then add 6 parts of magnesium stearate and 9 parts of silicon dioxide and mix for 4 minutes to form a mixture;
[0054] Step 4: Add the mixture into a high-efficiency mixer, disperse it evenly, and then fill it into capsules.
[0055] The relevant indicators of the obtained capsules are shown in Table 3.
[0056] Table 3 Dissolution index obtained in Example 3
[0057]
[0058] Example 4
[0059] The present embodiment provides a medroxyprogesterone acetate capsule and a preparation method thereof, the preparation method comprising the following steps:
[0060] Step 1: Mix 100 parts of medroxyprogesterone acetate, polyethylene glycol-6000 and 600 parts of a mixed solution of ethanol and chloroform (500 parts of ethanol and 100 parts of chloroform) to completely dissolve them for 10 minutes to form a homogeneous solution;
[0061] Step 2: spray drying the homogenized solution until the residual ethanol content is less than 0.4% and the residual chloroform content is less than 0.1%, to obtain solid dispersion particles;
[0062] Step 3: Pass the solid dispersion particles through a 60-mesh sieve, mix with 40 parts of pregelatinized starch, 40 parts of microcrystalline cellulose, and 12 parts of sodium carboxymethyl starch for 15 minutes, and then add 6 parts of magnesium stearate and 9 parts of silicon dioxide and mix for 4 minutes to form a mixture;
[0063] Step 4: Add the mixture into a high-efficiency mixer, disperse it evenly, and then fill it into capsules.
[0064] The relevant indicators of the obtained capsules are shown in Table 4.
[0065] Table 4 Dissolution index obtained in Example 4
[0066]
[0067] Through the screening of Examples 1-4, it was found that the addition of hydrophilic materials of povidone K30 in the prescription had the greatest influence on the dissolution of the capsules compared with the addition of hydrophilic materials of povidone K90, polyethylene glycol-4000, and polyethylene glycol-6000. By increasing the solubility of medroxyprogesterone acetate and accelerating the dissolution of medroxyprogesterone acetate, the dissolution rate reached 84.3% at 45 minutes, which is much greater than the 2020 edition of the Chinese Pharmacopoeia for the dissolution of medroxyprogesterone acetate capsules. Dissolution: Determined according to the dissolution and release determination method (General Rule 0931 Second Method), the dissolution conditions are 900 ml of 0.5% sodium dodecyl sulfate solution as the dissolution medium, the rotation speed is 50 revolutions per minute, and the operation is carried out according to the law. After 45 minutes of sampling, the dissolution amount of each particle should be greater than 50% of the labeled amount.
[0068] Example 5
[0069] The present embodiment provides a medroxyprogesterone acetate capsule and a preparation method thereof, the preparation method comprising the following steps:
[0070] Step 1: 100 parts of medroxyprogesterone acetate, 60 parts of povidone K30 and 600 parts of a mixed solution of ethanol and chloroform (500 parts of ethanol and 100 parts of chloroform) are mixed to completely dissolve them for 10 minutes to form a homogeneous solution;
[0071] Step 2: spray drying the homogenized solution until the residual ethanol content is less than 0.4% and the residual chloroform content is less than 0.1%, to obtain solid dispersion particles;
[0072] Step 3: Step 3: The solid dispersion particles are passed through a 60-mesh sieve, mixed with 40 parts of pregelatinized starch, 40 parts of microcrystalline cellulose, and 12 parts of croscarmellose sodium for 15 minutes, and then 6 parts of magnesium stearate and 9 parts of silicon dioxide are added and mixed for 4 minutes to form a mixture;
[0073] Step 4: Add the mixture into a high-efficiency mixer, disperse it evenly, and then fill it into capsules.
[0074] The relevant indicators of the obtained capsules are shown in Table 5.
[0075] Table 5 Dissolution index obtained in Example 5
[0076]
[0077] Example 6
[0078] The present embodiment provides a medroxyprogesterone acetate capsule and a preparation method thereof, the preparation method comprising the following steps:
[0079] Step 1: 100 parts of medroxyprogesterone acetate, 140 parts of povidone K30 and 600 parts of a mixed solution of ethanol and chloroform (500 parts of ethanol and 100 parts of chloroform) are mixed to completely dissolve them for 10 minutes to form a homogeneous solution;
[0080] Step 2: spray drying the homogenized solution until the residual ethanol content is less than 0.4% and the residual chloroform content is less than 0.1%, to obtain solid dispersion particles;
[0081] Step 3: Step 3: The solid dispersion particles are passed through a 60-mesh sieve, mixed with 40 parts of pregelatinized starch, 40 parts of microcrystalline cellulose, and 12 parts of croscarmellose sodium for 15 minutes, and then 6 parts of magnesium stearate and 9 parts of silicon dioxide are added and mixed for 4 minutes to form a mixture;
[0082] Step 4: Add the mixture into a high-efficiency mixer, disperse it evenly, and then fill it into capsules.
[0083] The relevant indicators of the obtained capsules are shown in Table 6.
[0084] Table 6 Dissolution index obtained in Example 6
[0085]
[0086] By comparing Examples 1, 5 and 6, it is found that the amount of the hydrophilic material of povidone added in the prescription also affects the dissolution rate of the capsule. When the amount of medroxyprogesterone acetate is controlled to 100 parts and the amount of the hydrophilic material of povidone K30 is controlled to 100 parts, the dissolution rate can reach 96.6% at 1 hour, and the dissolution index is the best relative to the addition amount of 60 parts and 140 parts. When the amount of the hydrophilic material of povidone is 140 parts, the dissolution rate is 84.8% at 1 hour. The possible reason for the analysis is that too much hydrophilic material of povidone as a carrier will encapsulate a small amount of active pharmaceutical ingredients, thereby slightly reducing the dissolution rate.
[0087] Example 7
[0088] The present embodiment provides a medroxyprogesterone acetate capsule and a preparation method thereof, the preparation method comprising the following steps:
[0089] Step 1: 100 parts of medroxyprogesterone acetate and 100 parts of povidone K30 were mixed with 800 parts of a mixed solution of ethanol and chloroform (667 parts of ethanol and 133 parts of chloroform) to completely dissolve them for 5 minutes to form a homogeneous solution;
[0090] Step 2: spray drying the homogenized solution until the residual ethanol content is less than 0.4% and the residual chloroform content is less than 0.1%, to obtain solid dispersion particles;
[0091] Step 3: Pass the solid dispersion particles through a 60-mesh sieve, mix with 40 parts of pregelatinized starch, 40 parts of microcrystalline cellulose, and 6 parts of cross-linked sodium carboxymethyl cellulose for 10 minutes, and then add 1.5 parts of magnesium stearate and 3 parts of silicon dioxide and mix for 3 minutes to form a mixture;
[0092] Step 4: Add the mixture into a high-efficiency mixer, disperse it evenly, and then fill it into capsules.
[0093] The relevant indicators of the obtained capsules are shown in Table 7.
[0094] Table 7 Dissolution index obtained in Example 7
[0095]
[0096] Example 8
[0097] The present embodiment provides a medroxyprogesterone acetate capsule and a preparation method thereof, the preparation method comprising the following steps:
[0098] Step 1: Mix 100 parts of medroxyprogesterone acetate and 100 parts of povidone K30 with 1000 parts of a mixed solution of ethanol and chloroform (833 parts of ethanol and 167 parts of chloroform) to completely dissolve them for 8 minutes to form a homogeneous solution;
[0099] Step 2: spray drying the homogenized solution until the residual ethanol content is less than 0.4% and the residual chloroform content is less than 0.1%, to obtain solid dispersion particles;
[0100] Step 3: Pass the solid dispersion particles through a 60-mesh sieve, mix with 40 parts of pregelatinized starch, 40 parts of microcrystalline cellulose, and 18 parts of low-substituted hydroxypropyl cellulose for 20 minutes, and then add 10.5 parts of magnesium stearate and 15 parts of silicon dioxide and mix for 5 minutes to form a mixture;
[0101] Step 4: Add the mixture into a high-efficiency mixer, disperse it evenly, and then fill it into capsules.
[0102] The relevant indicators of the obtained capsules are shown in Table 8.
[0103] Table 8 Dissolution index obtained in Example 8
[0104]
[0105] By comparing Examples 1, 7 and 8, it was found that changes in other excipients in the prescription or the mixing time had relatively little effect on the results.
[0106] Comparative Example 1
[0107] Referring to a drug for treating endometriosis and its preparation method in Example 1 of patent CN1887288A, a medroxyprogesterone acetate dispersible tablet was prepared, and its preparation method is as follows:
[0108] (1) Weigh 100 parts of medroxyprogesterone acetate, 23.8 parts of sodium starch glycolate, 17 parts of crospovidone, 17 parts of pregelatinized starch, and 178.8 parts of microcrystalline cellulose, and pass through a 100-mesh sieve to mix them evenly.
[0109] (2) Add an appropriate amount of 5% polyvinyl pyrrolidone ethanol solution to the fine powder of the raw materials and auxiliary materials, mix well and make a soft material.
[0110] (3) Press the soft material through a 20-mesh sieve to make particles.
[0111] (4) After the wet granules are prepared, they are immediately placed in an oven and dried at 60°C for 20 minutes.
[0112] (5) Use a 30-mesh sieve to sieve the particles, add silicon dioxide, mix well, and press into tablets.
[0113] The relevant indicators obtained are detailed in Table 9.
[0114] Table 9 Dissolution index obtained in comparative example 1
[0115]
[0116]
[0117] Comparative Example 2
[0118] The prescription is basically the same as in Example 1, except that medroxyprogesterone acetate and povidone K30 are not used to prepare the solid dispersion, and the rest of the process is basically the same as in Example 1.
[0119] The preparation method is as follows:
[0120] Step 1: Mix 100 parts of medroxyprogesterone acetate raw material and 100 parts of povidone K30 through a 60-mesh sieve for later use (there is no step of preparing a solid dispersion in the middle)
[0121] Step 2: Mix the material of step 1 with 40 parts of pregelatinized starch, 40 parts of microcrystalline cellulose, and 12 parts of sodium carboxymethyl starch for 15 minutes, then add 6 parts of magnesium stearate and 9 parts of silicon dioxide and mix for 4 minutes to form a mixture;
[0122] Step 3: Add the mixture into a high-efficiency mixer, disperse it evenly, and then fill it into capsules.
[0123] The relevant indicators obtained are detailed in Table 10.
[0124] Table 10 Dissolution index obtained in comparative example 2
[0125]
[0126] Comparative Example 3
[0127] The prescription is basically the same as that of Example 1, except that no povidone K30 is added and the raw materials are not treated.
[0128] On the basis of Example 1, medroxyprogesterone acetate was passed through a 60-mesh sieve (without the step of preparing a solid dispersion in the middle) to prepare a medroxyprogesterone acetate capsule, and the preparation method thereof is as follows:
[0129] Step 1: Mix 100 parts of medroxyprogesterone acetate, 40 parts of pregelatinized starch, 40 parts of microcrystalline cellulose, and 12 parts of sodium carboxymethyl starch for 15 minutes, then add 6 parts of magnesium stearate and 9 parts of silicon dioxide and mix for 4 minutes to form a mixture;
[0130] Step 2: Add the mixture into a high-efficiency mixer, disperse it evenly, and then fill it into capsules.
[0131] The relevant indicators obtained are detailed in Table 11.
[0132] Table 11 Dissolution index obtained in comparative example 3
[0133]
[0134] By comparing the data of Example 1 and Comparative Examples 1-3, it is found that not adding hydrophilic materials in the prescription or reducing the step of solid dispersion in the process greatly reduces the dissolution rate of the active ingredient to less than 60%. The present invention unexpectedly found that the use of hydrophilic materials and the step of preparing solid dispersions greatly increase the dissolution rate of the active ingredient.
[0135] Long-term stability test
[0136] The most preferred embodiment 1 among the medroxyprogesterone acetate dispersion capsules prepared according to embodiments 1-4, the medroxyprogesterone acetate dispersible tablets prepared according to comparative examples 1-3, and the ordinary capsule samples were subjected to long-term stability test at room temperature. The results are shown in Table 12.
[0137] Determination of active ingredient content
[0138] Determined by high performance liquid chromatography (General Rule 0512).
[0139] Test solution: Take an appropriate amount of the product, dissolve it in methanol and dilute it to make a solution containing about 0.8 mg per 1 ml.
[0140] Control solution: Accurately measure 1 ml of the test solution, place it in a 50 ml volumetric flask, dilute to the mark with methanol, and shake well.
[0141] System suitability solution: Take appropriate amounts of medroxyprogesterone acetate and norethindrone, dissolve in methanol and dilute to make a mixed solution containing approximately 0.16 mg of each per 1 ml.
[0142] Chromatographic conditions: octadecylsilane bonded silica gel as filler; methanol-water (70:30) as mobile phase; detection wavelength at 254 nm; injection volume 10 μl.
[0143] System suitability requirements: In the chromatogram of the system suitability solution, the theoretical plate number calculated based on the medroxyprogesterone acetate peak should be no less than 2000, the separation between the medroxyprogesterone acetate peak and the norethindrone peak should be greater than 3.0, and the separation between the impurity peak before the medroxyprogesterone acetate peak and the medroxyprogesterone acetate peak should meet the requirements.
[0144] Determination method: Accurately measure the test solution and the control solution, inject them into the liquid chromatograph respectively, and record the chromatogram to 1.5 times the retention time of the main component peak.
[0145] Limits: If there are impurity peaks in the chromatogram of the test solution, there shall be no more than 4, the area of a single impurity peak shall not be greater than 0.5 times (1.0%) the area of the main peak of the control solution, the sum of the areas of the impurity peaks shall not be greater than 0.75 times (1.5%) the area of the main peak of the control solution, and peaks less than 0.05 times (0.1%) the area of the main peak of the control solution shall be ignored
[0146] Table 12 Medroxyprogesterone acetate active ingredient content
[0147]
[0148] It can be seen from Table 12 that during the 6-month storage process, the active ingredient content of the sample prepared in Example 1 of the present invention is higher than that of the samples prepared in Comparative Examples 1 to 3 after 6 months of long-term conditions. Conclusion: The sample in Example 1 has good stability and meets the requirements of the Pharmacopoeia.
Claims
1. A medroxyprogesterone acetate capsule, characterized in that: The invention comprises medroxyprogesterone acetate, a hydrophilic material, a filler, a disintegrant, a lubricant, a glidant and a solvent, wherein the hydrophilic material is selected from one of povidone K30, povidone K90, polyethylene glycol-4000 or polyethylene glycol-6000.
2. The medroxyprogesterone acetate capsule according to claim 1, characterized in that: The filler includes one or more of pregelatinized starch and microcrystalline cellulose; the disintegrant includes one or more of sodium carboxymethyl starch, cross-linked sodium carboxymethyl cellulose, and low-substituted hydroxypropyl cellulose; the lubricant includes magnesium stearate; and the glidant includes silicon dioxide.
3. The medroxyprogesterone acetate capsule according to claim 1, characterized in that: The hydrophilic material is povidone K30.
4. The medroxyprogesterone acetate capsule according to claim 1, characterized in that: The solvent includes a mixed solution of ethanol and chloroform, wherein the volume ratio of ethanol to chloroform is 5:
1.
5. The medroxyprogesterone acetate capsule according to any one of claims 1 to 4, characterized in that The weight contents of the components of the medroxyprogesterone acetate capsule are: 100 parts of medroxyprogesterone acetate, 60-140 parts of hydrophilic material, 1-80 parts of filler, 6-18 parts of disintegrant, 1.5-10.5 parts of lubricant, 3-15 parts of glidant and 600-1000 parts of solvent.
6. The method according to claim 5, characterized in that The weight content of each component of the medroxyprogesterone acetate capsule is: 100 parts of medroxyprogesterone acetate, 60-140 parts of povidone K30, 6-18 parts of sodium carboxymethyl starch, 1.5-10.5 parts of magnesium stearate, 3-15 parts of silicon dioxide, and 600-1000 parts of a mixed solution of ethanol and chloroform; in the filler, microcrystalline cellulose and / or pregelatinized starch are 1-80 parts.
7. A method for preparing the medroxyprogesterone acetate capsule according to any one of claims 1 to 6, characterized in that: The preparation method comprises the following steps: Step 1: Mixing medroxyprogesterone acetate, a hydrophilic material and a solvent to completely dissolve them to form a homogeneous solution; Step 2: spray drying the homogenized solution to obtain solid dispersion particles; Step 3: sieving the solid dispersion particles and mixing them with a filler, a disintegrant, a lubricant and a glidant to form a mixture; Step 4: Add the mixture into a high-efficiency mixer, disperse it evenly, and then fill it into capsules.
8. The method according to claim 7, characterized in that: In the step 1, the mixing time is 5-10 min, preferably 10 min.
9. The method according to claim 7, characterized in that: In the step 2, the termination condition of the drying is that the residual ethanol content in the solid dispersion particles is less than 0.4% and the residual chloroform content is less than 0.1%.
10. The method according to claim 7, characterized in that: In the step three, the solid dispersion particles are first mixed with a filler and a disintegrant, and then mixed with a lubricant and a glidant.
